Recruiting studies: Oligometastatic Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192 Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup
Phase N/A · 2 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT07441941 En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT06120426 Metastases Directed Therapy for Oligometastatic Breast Cancer
NA · 1 location(s) · National Cancer Institute, Egypt · NCT06144346 Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
Phase 3 · 6 location(s) · Vastra Gotaland Region · NCT06141070 Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
NA · 1 location(s) · University Health Network, Toronto · NCT06668454 Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Pros
Phase 2 · 15 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT07717268 PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Phase N/A · 1 location(s) · Fudan University · NCT07697859 Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
Phase 2 · 14 location(s) · MedSIR · NCT06180356 The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304 Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07686016 Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease
NA · 11 location(s) · Gitte Fredberg Persson MD PhD · NCT06356779 Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06546267 SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 · 6 location(s) · Mayo Clinic · NCT06205316 OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Phase 2 · 2 location(s) · Karen-Lise Garm Spindler · NCT04680260 Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT05893381 Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Opt
Phase N/A · 1 location(s) · Klinikum Esslingen · NCT04926584 Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
Phase 2 · 1 location(s) · Tata Memorial Hospital · NCT05277844 OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
Phase 2 · 1 location(s) · National Medical Research Radiological Centre of the Ministr · NCT06856603 OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for
NA · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06462963 Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
NA · 1 location(s) · The University of Texas Health Science Center at San Antonio · NCT07340151 stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Databas
Phase N/A · 28 location(s) · Istituto Clinico Humanitas · NCT07397585 Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Fifth Affiliated Hospital, Sun Yat-Sen University · NCT05290194 A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastati
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07455019 Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Phase 3 · 1 location(s) · Roswell Park Cancer Institute · NCT06563388 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · 147 location(s) · Novartis Pharmaceuticals · NCT05939414 Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Ca
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03161522 PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients
NA · 1 location(s) · National Cancer Institute, Naples · NCT04854213 Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
NA · 2 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT04852588 Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography
EARLY_Phase 1 · 1 location(s) · Katelyn Atkins · NCT06373497

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.